First-in-Class Dual Hybrid Carbonic Anhydrase Inhibitors and Transient Receptor Potential Vanilloid 1 Agonists Revert Oxaliplatin-Induced Neuropathy

MLA

Andrea Angeli, et al. “First-in-Class Dual Hybrid Carbonic Anhydrase Inhibitors and Transient Receptor Potential Vanilloid 1 Agonists Revert Oxaliplatin-Induced Neuropathy.” Journal of Medicinal Chemistry, vol. 66, Jan. 2023, pp. 1616–33. EBSCOhost, https://doi.org/10.1021/acs.jmedchem.2c01911.

APA

Andrea Angeli, Laura Micheli, Fabrizio Carta, Marta Ferraroni, Tracey Pirali, Asia Fernandez Carvajal, Antonio Ferrer Montiel, Lorenzo Di Cesare Mannelli, Carla Ghelardini, & Claudiu T. Supuran. (2023). First-in-Class Dual Hybrid Carbonic Anhydrase Inhibitors and Transient Receptor Potential Vanilloid 1 Agonists Revert Oxaliplatin-Induced Neuropathy. Journal of Medicinal Chemistry, 66, 1616–1633. https://doi.org/10.1021/acs.jmedchem.2c01911

Chicago

Andrea Angeli, Laura Micheli, Fabrizio Carta, Marta Ferraroni, Tracey Pirali, Asia Fernandez Carvajal, Antonio Ferrer Montiel, Lorenzo Di Cesare Mannelli, Carla Ghelardini, and Claudiu T. Supuran. 2023. “First-in-Class Dual Hybrid Carbonic Anhydrase Inhibitors and Transient Receptor Potential Vanilloid 1 Agonists Revert Oxaliplatin-Induced Neuropathy.” Journal of Medicinal Chemistry 66 (January): 1616–33. doi:10.1021/acs.jmedchem.2c01911.